Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Mutational profiles of MDS patients undergoing allo-HSCT

Ivan Moiseev • 30 Aug 2020
EBMT 2020
Myelodysplastic Syndromes

Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, discusses the outcomes and mutational profile of patients with myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ivan Moiseev

1:01
Significance of MRD negativity in Ph-negative ALL
Ivan Moiseev • 1 Sep 2020
0:53
GO-FLAG: bridge therapy to allo-SCT in R/R AML
Ivan Moiseev • 30 Aug 2020
1:27
Impact of post-transplant TKIs on long-term outcomes of allo-HSCT in ALL
Ivan Moiseev • 1 Sep 2020
1:06
Allo-HSCT in BCR-ABL-negative MPN pretreated with JAK inhibitors
Ivan Moiseev • 1 Sep 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals